Literature DB >> 29992246

α7 Nicotinic Acetylcholine Receptor Regulates the Function and Viability of L Cells.

Dawei Wang1,2, Qinghe Meng2, Colin A Leech2, Natesh Yepuri2, Linlin Zhang2, George G Holz3,4, Chunting Wang5, Robert N Cooney2.   

Abstract

Enteroendocrine L cells secrete the incretin hormone glucagon-like peptide-1 (GLP-1), and they also express the α7 nicotinic acetylcholine receptor (α7nAChR), which may regulate GLP-1 secretion. Here, GTS-21, a selective α7nAChR agonist, was used to examine the effect of α7nAChR activation in L-cell lines, mouse intestinal primary cell cultures, and C57BL/6 mice. GTS-21 stimulated GLP-1 secretion in vitro, and this effect was attenuated by an α7nAChR antagonist or by α7nAChR-specific small interfering RNA. Under in vitro cell culture conditions of glucotoxicity, GTS-21 restored GLP-1 secretion and improved L-cell viability while also acting in vivo to raise levels of circulating GLP-1 in mice. To assess potential signaling mechanisms underlying these actions of GTS-21, we first monitored Ca2+, cAMP, and phosphatidylinositol 3-kinase (PI3K) activity. As expected for a GLP-1 secretagogue promoting Ca2+ influx through α7nAChR cation channels, [Ca2+]i increased in response to GTS-21, but [cAMP]i was unchanged. Surprisingly, pharmacological inhibition of growth factor signaling pathways revealed that GTS-21 also acts on the PI3K-protein kinase B-mammalian target of rapamycin pathway to promote L-cell viability. Moreover, the Ca2+ chelator BAPTA-AM counteracted GTS-21‒stimulated PI3K activity, thereby indicating unexpected crosstalk of L-cell Ca2+ and growth factor signaling pathways. Collectively, these data demonstrate that α7nAChR activation enhances GLP-1 secretion by increasing levels of cytosolic Ca2+ while also revealing Ca2+- and PI3K-dependent processes of α7nAChR activation that promote L-cell survival.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29992246      PMCID: PMC6456923          DOI: 10.1210/en.2018-00433

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.

Authors:  Qinghe Meng; Oleg G Chepurny; Colin A Leech; Napat Pruekprasert; Megan E Molnar; James Jason Collier; Robert N Cooney; George G Holz
Journal:  Diabetes Obes Metab       Date:  2022-04-07       Impact factor: 6.408

Review 2.  Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.

Authors:  Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney
Journal:  Rev Endocr Metab Disord       Date:  2020-08-26       Impact factor: 6.514

Review 3.  Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?

Authors:  C Meurot; C Jacques; C Martin; L Sudre; J Breton; R Rattenbach; K Bismuth; F Berenbaum
Journal:  J Orthop Translat       Date:  2022-02-25       Impact factor: 5.191

4.  Activation of α7 Nicotinic Acetylcholine Receptor Upregulates HLA-DR and Macrophage Receptors: Potential Role in Adaptive Immunity and in Preventing Immunosuppression.

Authors:  Andrei E Siniavin; Maria A Streltsova; Denis S Kudryavtsev; Irina V Shelukhina; Yuri N Utkin; Victor I Tsetlin
Journal:  Biomolecules       Date:  2020-03-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.